David Turkaly
Stock Analyst at JMP Securities
(2.33)
# 2,524
Out of 4,732 analysts
139
Total ratings
41.98%
Success rate
-1.93%
Average return
Main Sectors:
Stocks Rated by David Turkaly
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LNTH Lantheus Holdings | Reiterates: Market Outperform | $112 | $91.47 | +22.44% | 8 | Jan 14, 2025 | |
| SYK Stryker | Reiterates: Market Perform | n/a | $383.42 | - | 1 | Jan 7, 2025 | |
| STE STERIS | Reiterates: Market Outperform | $265 | $209.62 | +26.42% | 16 | Nov 18, 2024 | |
| NVRO Nevro | Reiterates: Market Perform | n/a | $4.57 | - | 14 | Nov 12, 2024 | |
| ENOV Enovis | Initiates: Market Outperform | $62 | $46.63 | +32.96% | 1 | Oct 3, 2024 | |
| APYX Apyx Medical | Reiterates: Market Perform | n/a | $1.39 | - | 5 | Sep 16, 2024 | |
| KIDS OrthoPediatrics | Reiterates: Market Outperform | $50 | $27.16 | +84.09% | 9 | Sep 13, 2024 | |
| STIM Neuronetics | Maintains: Market Outperform | $7 → $3 | $2.46 | +21.95% | 7 | Aug 14, 2024 | |
| HAE Haemonetics | Reiterates: Market Outperform | $125 | $73.49 | +70.09% | 10 | Aug 13, 2024 | |
| TELA TELA Bio | Maintains: Market Outperform | $15 → $12 | $2.69 | +346.10% | 5 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $17 → $20 | $18.09 | +10.56% | 6 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $40 → $35 | $24.10 | +45.23% | 13 | Jul 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $23 → $20 | $10.88 | +83.82% | 4 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $32 | $16.69 | +91.73% | 6 | May 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $18.13 | - | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $285 | $181.27 | +57.22% | 14 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $160 → $140 | $109.56 | +27.78% | 13 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $90.80 | - | 1 | May 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7 → $4 | $1.97 | +103.56% | 4 | Apr 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $5 | $9.66 | -48.24% | 1 | Oct 6, 2017 |
Lantheus Holdings
Jan 14, 2025
Reiterates: Market Outperform
Price Target: $112
Current: $91.47
Upside: +22.44%
Stryker
Jan 7, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $383.42
Upside: -
STERIS
Nov 18, 2024
Reiterates: Market Outperform
Price Target: $265
Current: $209.62
Upside: +26.42%
Nevro
Nov 12, 2024
Reiterates: Market Perform
Price Target: n/a
Current: $4.57
Upside: -
Enovis
Oct 3, 2024
Initiates: Market Outperform
Price Target: $62
Current: $46.63
Upside: +32.96%
Apyx Medical
Sep 16, 2024
Reiterates: Market Perform
Price Target: n/a
Current: $1.39
Upside: -
OrthoPediatrics
Sep 13, 2024
Reiterates: Market Outperform
Price Target: $50
Current: $27.16
Upside: +84.09%
Neuronetics
Aug 14, 2024
Maintains: Market Outperform
Price Target: $7 → $3
Current: $2.46
Upside: +21.95%
Haemonetics
Aug 13, 2024
Reiterates: Market Outperform
Price Target: $125
Current: $73.49
Upside: +70.09%
TELA Bio
Aug 13, 2024
Maintains: Market Outperform
Price Target: $15 → $12
Current: $2.69
Upside: +346.10%
Aug 9, 2024
Maintains: Market Outperform
Price Target: $17 → $20
Current: $18.09
Upside: +10.56%
Jul 30, 2024
Maintains: Market Outperform
Price Target: $40 → $35
Current: $24.10
Upside: +45.23%
May 9, 2024
Maintains: Market Outperform
Price Target: $23 → $20
Current: $10.88
Upside: +83.82%
May 7, 2024
Reiterates: Market Outperform
Price Target: $32
Current: $16.69
Upside: +91.73%
Apr 22, 2024
Reiterates: Market Perform
Price Target: n/a
Current: $18.13
Upside: -
Feb 23, 2024
Reiterates: Market Outperform
Price Target: $285
Current: $181.27
Upside: +57.22%
Nov 13, 2023
Maintains: Market Outperform
Price Target: $160 → $140
Current: $109.56
Upside: +27.78%
May 24, 2023
Reiterates: Market Perform
Price Target: n/a
Current: $90.80
Upside: -
Apr 13, 2023
Maintains: Outperform
Price Target: $7 → $4
Current: $1.97
Upside: +103.56%
Oct 6, 2017
Initiates: Outperform
Price Target: $5
Current: $9.66
Upside: -48.24%